Case report shows effective treatment for late-onset Pneumocystis jirovecii pneumonia in transplant recipients, suggesting a viable option for those with allergies.
This case shows that late-onset Pneumocystis jirovecii pneumonia may develop years after transplantation, particularly after rituximab therapy and without prophylaxis. Intravenous trimethoprim-sulfamethoxazole desensitization can be a safe and effective therapeutic option for transplant recipients with a trimethoprim-sulfamethoxazole allergy, enabling use of the optimal antimicrobial agent.
No takes yet. Share an insight, caveat, or question.
Banu Yılmaz (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: